Skin cancers, which can amendable for surgery, are removed straightaway.

A recent trial indicates giving some immunotherapy treatment before the operation is better than immediate surgery.

Also avoiding additional treatment after surgery in those who have responded well to prior immunotherapy is a bonus through this personalised approach.

This approach is likely to become the standard of care.

References

1. NEJM. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

2. ASCO 2024. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

3. ASCO 2024 Daily news. NADINA: Neoadjuvant Ipilimumab Plus Nivolumab Poised to Become a New Standard of Care for Macroscopic Stage III Melanoma

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.